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Characterization of acute inhibition of Na/H exchanger NHE-3 phenylalanine (L-DOPA), derived from the plasma and
by dopamine in opossum kidney cells. glomerular filtrate by aromatic amino acid decarboxyl-
Background. Dopamine (DA) is a principal natriuretic hor- ase, and induces natriuresis in a paracrine/autocrine fash-mone that defends extracellular fluid volume from a Na load.
ion [9–13]. Part of the natriuretic action of DA is attrib-Natriuresis is effected partly through inhibiting the proximal
uted to its hemodynamic effects on renal plasma flowtubule Na/H exchanger NHE-3. Changes in NHE-3 phosphory-
lation is one mechanism by which NHE-3 activity is regulated. and filtration fraction [14–16], but the principal effector
Methods. We used opossum kidney (OK) cells to character- of natriuresis is via direct action on the tubular epithe-
ize the differential and synergistic effects of DA receptor sub-
lium [17–21]. In the proximal tubule, where the mosttype-1 (DA1) and -2 (DA2) agonists and the effect of blockade
significant amount of natriuresis is induced, DA exertsof protein kinase A (PKA) or protein kinase C (PKC) on NHE-3
activity and phosphorylation. its action via inhibition of the two principal Na transport-
Results. DA and DA1 agonists inhibited NHE-3 activity, and ers: the apical Na/H exchanger [22–27] and basolateral
DA1 antagonist blocked the effect of either DA or DA1 agonist. Na,K-ATPase [28–32].DA2 agonist alone had no effect, but DA2 antagonist reduced Dopamine receptors consist of five genetic isoformsthe DA effect on NHE-3 activity. DA1 and DA2 agonists to-
and can be broadly divided into two categories: type 1-gether were more potent than DA1 alone. PKA inhibition elimi-
nated the effect of DA1 agonist and partially blocked the effect like (DA1) and type 2-like (DA2) [33–37]. The action of
of DA on NHE-3 activity. PKC inhibition did not block the DA1 is coupled to Gas, while DA2 is coupled to Ga1/DA effect. DA1 agonist and PKA activation phosphorylated Gao. Both subtypes are differentially expressed but areNHE-3 on identical sites. Despite lack of effect on NHE-3
present throughout the glomerulus, renal vasculature,activity, DA2 agonists increased NHE-3 phosphorylation. DA-
induced NHE-3 phosphorylation was distinct from DA1 and and renal tubules [33–37]. The functional inhibition of
PKA but closely resembled DA2. the proximal tubule Na,K-ATPase has been postulated
Conclusion. We postulate the following: (1) DA modifies to require dual DA1 and DA2 activation [30, 31], involvesNHE-3 phosphorylation by activating PKA through DA1 and protein kinase A (PKA), protein kinase C (PKC), andby other kinases/phosphatases via DA2. (2) DA1 is sufficient
phospholipase A2 pathways, as well as the 32 kD DAto inhibit NHE-3, while DA2 is insufficient but plays a syner-
gistic role by altering NHE-3 phosphorylation. adenosine monophosphate-regulated phosphoprotein,
DARPP-32 [38–45]. As for regulation of the apical mem-
brane Na/H exchanger, previous studies suggested that
Numerous studies have demonstrated the critical role DA1 is the predominant pathway [22, 23, 25, 26] and that
of intrarenal rather than systemic or neuroneal-derived the inhibition is partially dependent on PKA [22, 26].
dopamine (DA) in renal Na homeostasis in response to Contributions from DA2 and the phospholipase C/PKC
both acute and chronic salt loading [1–8]. DA is synthe- pathway have been suggested [46, 47]. Since signaling
sized in the renal proximal tubule from 3,4-dihydroxy- cascades of both DA1 and DA2 receptors are coupled to
kinases and phosphatases, one mechanism by which DA
regulates apical membrane NHE activity may be via phos-Key words: natriuresis, proximal tubule, dopamine receptors, protein
kinase, phosphorylation phorylation/dephosphorylation of the apical membrane
Na/H exchanger. The effect of DA on NHE-3 phosphor-Received for publication February 15, 2000
ylation has not been examined.and in revised form May 26, 2000
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Na/H exchanger (NHE) is predominantly the NHE-3 ports. NHE-3 activity was measured fluorimetrically with
the pH-sensitive dye BCECF as Na1-dependent pHi re-isoform [49–51]. Previous studies on the effect of DA
on apical membrane NHE involved adding DA to corti- covery (dpHi/dt) after an acid load (NH4Cl prepulse/
withdrawal) as previously described [55, 56]. Cells oncal slices [22, 26], suspended tubules [23, 24], or mem-
brane vesicles [25, 27]. Further studies of the effect of permeable supports were continuously perfused from
both the apical and basolateral compartments. A fewDA on apical membrane NHE requires a cell culture
model and NHE-3 isoform-specific reagents. In this study, experiments were done independently with cells on both
permeable supports and glass cover slips. BCECF cali-we used OK cells, a renal epithelial cell line expressing
native NHE-3 [52], and DA receptors [53, 54], to charac- bration curves to convert fluorescence to pHi were ob-
tained using the ionophore nigericin at varying levels ofterize the effect of DA on NHE-3 with the following
objectives: (1) to define the roles of DA1 and DA2, (2) extracellular pH.
to define the roles of PKA and PKC, and (3) to examine
In vivo phosphorylationwhether DA alters NHE-3 phosphorylation.
After incubation in phosphate-free DMEM (60 min),
OK cells were labeled with phosphate-free medium con-
METHODS
taining 32P-orthophosphate (500 Ci/mL; 120 min). Ago-
Materials nists were added and cells were washed, lyzed with RIPA
buffer [in mmol/L: 300 NaCl, 80 NaF, 50 Tris-HCl pHAll chemicals were purchased from Sigma (St. Louis,
MO, USA) except as follows: Dulbecco’s modified Ea- 7.4, 5 ethylenediaminetetraacetic acid (EDTA), 10 eg-
tazic acid (EGTA), 25 Na pyrophosphate, 1 activatedgle’s medium (DMEM) and fetal bovine serum (FBS)
from GIBCO/BRL (Grand Island, NY, USA); phorbol Na1 orthovanadate, 50 b-glycerophosphate, 0.5 dithi-
othreitol (DTT); Triton X-100 1% (vol:vol), deoxycho-12-myristate 13-acetate (PMA) from LC Laboratories
(Woburn, MA, USA); 29,79-bis-(2-carboxyethyl)-5-(and- late 0.5% (wt:vol), sodium dodecyl sulfate (SDS) 0.1%
(wt:vol); in mg/mL: 100 phenylmethylsulfonyl fluoride6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM)
from Molecular Probes (Eugene, OR, USA); 32P-ortho- (PMSF), 4 leupeptin, 4 aprotinin, 10 pepstatin], and cen-
trifuged (109,000 3 g at rmax, 50,000 r.p.m., 25 minutes,phosphate from New England Nuclear (Boston, MA,
USA); enhanced chemiluminescence (ECL) from Amer- 28C; Beckman TLX/TLA 100.3 rotor; Beckman Instru-
ments, Fullerton, CA, USA), and the supernatant wassham (Arlington Heights, IL, USA); N-tyrosyl-L-phenyl-
alanine chloromethyl ketone (TPCK)-treated trypsin from retrieved and mixed with an equal amount of water to
lower salt and detergent concentrations. NHE-3 was im-Worthington Biochem Corp. (Freehold, NJ, USA); peni-
cillin and streptomycin from Whittaker MA Bioproducts munoprecipitated using a polyclonal antisera directed
against a chimeric protein composed of maltose binding(Walkersville, MD, USA); bromocriptine mesylate, quin-
pirole, and SKF38393 from Tocris Cookson Inc. (St. Louis, protein and opossum NHE-3 amino acids 484 to 839
(antiserum #5683 at 1:500 dilution, vol:vol). ImmunoblotsMO, USA); calphostin C from Calbiochem-Novabio-
chem (San Diego, CA, USA), SCH23390, quinpirole, and were performed with antiserum #5683 (1:1000) and goat
anti-rabbit antibody (1:5000) using ECL. The 32P contentsulpiride from Research Biochemicals Inc. (Natick, MA,
USA); fenoldopam from Neurex; and PY20 antiphos- of NHE-3 was visualized by autoradiography on the same
filters after decay of ECL. Both signals were quantitatedphotyrosine monoclonal antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The rat poly- by densitometry, and changes in phosphorylation were
normalized to the antigenic signal.clonal PKC isoenzyme-specific antisera were a generous
gift from Sloan Stribling and Dr. Yusuf Hannun from
NHE-3 mobility shift assay and in vitro treatment withDuke University (Durham, NC, USA).
alkaline phosphatase
Cell culture and Na/H exchanger activity In addition to 32P incorporation, NHE-3 whole protein
phosphorylation was also assessed by a mobility shiftOpossum kidney (OK) cells were passed in high glucose
DMEM, supplemented with Na pyruvate (1 mmol/L), assay. After incubating OK cells with DA, NHE-3 was
immunoprecipitated as described. SDS-polyacrylamideFBS (10%, vol:vol), penicillin (100 U/mL), and strepto-
mycin (100 mg/mL) on Teflon filters (0.4 mm, Millicell- gel electrophoresis (SDS-PAGE; 6% gel with 80 kD
marker ran to the edge of the gel), and immunoblot wasCM; Millipore, Bedford, MA, USA) for activity assays.
Confluent monolayers were rendered quiescent by se- then performed. For treatment with alkaline phospha-
tase, we modified a protocol described by Jou et al [57].rum removal for 48 hours prior to experimentation. For
phosphorylation experiments, cells were grown on either In brief, protein-A Sepharose beads with the antibody-
antigen complex were washed three times with RIPAplastic plates or polycarbonate filters. There were no
appreciable quantitative or qualitative differences in the and reaction buffer twice (in mmol/L: Tris-HCl 50, pH
8.5, PMSF 2, MgCl2 8; b-mercaptoethanol 0.1% (vol:vol)],resulting phosphorylation patterns between the two sup-
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and resuspended in 45 mL reaction buffer containing 10 U pernatant was retained as the cytosolic fraction. The pellet
calf intestine alkaline phosphatase. After incubation at was solubilized in buffer A with 1% (vol:vol) NP-40 and
378C for 90 minutes, the reaction was terminated by was centrifuged (109,000 3 g, 25 min), and the superna-
adding polyacrylamide gel loading buffer. tant was retained as the solubilized membrane fraction.
SDS-PAGE and immunoblot were then performed.
Tryptic phosphopeptide mapping and phosphoamino
acid analysis Statistical analysis
In vivo phosphorylated NHE-3 was immunoprecipi- Comparisons between two groups were performed
tated, fractionated by SDS-PAGE, and transferred to with unpaired t tests. Differences between multiple groups
nitrocellulose membrane. Membrane pieces correspond- were evaluated by analysis of variance (ANOVA).
ing to the phosphorylated NHE-3 protein were localized
by autoradiography, excised, and placed in 100 mmol/L
RESULTSacetic acid containing 0.5% polyvinylpyrrolidone at 378C
for 30 minutes, washed and digested with 15 mg TPCK- Acute inhibition of NHE-3 activity by dopamine:
treated trypsin in 0.05 mol/L NH4HCO3 at 378C. The Dose and time dependence
released phosphopeptides were repeatedly washed and Incubating OK cells with DA for 15 or 30 minutes
lyophilized until no salt residues were visible and were significantly inhibited NHE activity at concentrations be-
resuspended in electrophoresis buffer [per liter: 25 mL tween 1025 and 1023 mol/L. Maximal inhibition of 63%
88% (wt/vol) formic acid, 78 mL glacial acetic acid, 897 was achieved at 30 minutes of incubation with 1023 mol/L
mL deionized water, pH 1.95] and fractionated as pre- DA (Fig. 1A). At 1024 mol/L, the inhibition was signifi-
viously described [58, 59]. In brief, the sample was spot- cant between 5 and 30 minutes (maximal at 30 minutes,
ted on a cellulose thin layer chromatography (TLC) plate 40%), and by 60 minutes, the effect was reversed (Fig.
and resolved on a Hunter electrophoresis apparatus 1B). This recovery was due to degradation of DA rather
(HTLE 7000; CBS Scientific Co., Del Mar, CA, USA) at than desensitization because readdition of fresh DA
1.0 kV for 40 minutes. Separation in the second dimension once again led to inhibition (Fig. 1B). No significant
was achieved by ascending chromatography [375:250:75: difference was detected between apical versus basolat-
300 (vol:vol) n-butanol, pyridine, glacial acetic acid, de-
eral addition of DA (1024 mol/L DA 3 20 min: 34%
ionized water], and the phosphopeptides were visualized
inhibition apical vs. 28% inhibition basolateral; N 5 5
by autoradiography. Phosphoamino acid analysis was
each; P 5 0.42 apical vs. basolateral, P 5 0.01 DA vs.performed by two-dimensional electrophoresis [59]. Pu-
control for both apical and basolateral, ANOVA).rified phosphoproteins were hydrolyzed by boiling in 6
mol/L HCl, and 32P-labeled amino acids were electropho- Acute inhibition of NHE-3 activity by DA:
retically resolved on a Hunter electrophoresis unit (first DA1 versus DA2 pathway
dimension: 2.2% formic acid, 7.8% acetic acid, pH 1.9;
Selective activation of the DA1 receptor using the DA1second dimension: 5% acetic acid, 0.5% pyridine, pH 3.5)
agonist SKF38393 (1025 mol/L) or fenoldopam (1025along with the cold P-Ser, P-Thr, and P-Tyr standards.
mol/L) inhibited NHE-3 activity by 15 and 20%, respec-Phosphoamino acids were identified by autoradiography
tively (SKF38393 vs. control, P , 0.05; fenoldopam vs.and aligned with ninhydrin-stained standards.
control, P , 0.05, ANOVA), which was significantly less
than the 34% inhibition by equimolar 1025 mol/L DAPKCa translocation assay
(DA vs. control; P , 0.01, SKF38393 vs. DA, P , 0.05,The total cellular content of PKC isoforms (a, b1, b2,
fenoldopam vs. DA, P , 0.05, ANOVA; Fig. 2). Theg, d and e ) were measured by immunoblots with polyclonal
inhibitory effects of SKF38393, fenoldopam, or DA werePKC isoenzyme-specific antiserum and goat antirabbit an-
completely eliminated by coincubation with the specifictibody (dilutions: PKCa: 18: 1/10000, 28: 1/20000; PKCb1:
DA1 antagonist SCH23390 (1026 mol/L, 15 min), whereas18: 1/2000, 28: 1/2000; PKCb2: 18: 1/2000, 28: 1/2000; PKCg:
SCH23390 alone had no effect on baseline NHE activity18: 1/5000, 28: 1/10000; PKCd: 18: 1/20000, 28: 1/40000;
(3% inhibition, P 5 0.67, ANOVA). The role of DA2 wasPKCe 18: 1/20000, 28: 1/20000). Five percent albumin was
examined using the agonists bromocriptine (1025 mol/L)used as blocking agent, except for the two b isoforms
and quinpirole (1025 mol/L) or the antagonist sulpiride(5% powdered milk). PKC translocation was studied as
(1025 mol/L). Neither bromocryptine nor quinpirole hadpreviously described [60]. Cells were treated with the
an effect on NHE-3 activity (Fig. 3). In the presence ofappropriate agonist for 30 minutes, homogenized in
sulpiride, DA had a slightly smaller effect on NHE-3 activ-buffer A [in mmol/L: 20 Tris-HCl pH 7.5, 1 EDTA, 10
ity compared with DA alone (DA, 36% inhibition; DA 1EGTA, 1.0 PMSF, 0.5 leupeptin, 0.15 pepstatin, 1 DTT],
sulpiride, 24% inhibition; P , 0.05, ANOVA). Althoughand centrifuged (109,000 3 g at rmax, 50,000 r.p.m., 25
min, 28C; Beckman TLX/TLA 100.3 rotor), and the su- the DA2 agonist alone had no effect on NHE-3 activity,
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Fig. 2. DA receptor type 1 (DA1) pathway. Data are expressed as
percentage activity of control (h). Bars and error bars represent means
and standard errors, respectively. Abbreviations are: SKF, SKF38393;
Fen, fenoldopam; dopamine, DA. OK cells were incubated for 15 min-
utes with the DA1 agonists SKF (1026 mol/L), Fen (1025 mol/L), or
DA (1025 mol/L) with or without the DA1 antagonist SCH23390 (1026
mol/L). Number of independent experiments (N) each consisting of a
pair of control and agonist(s)-treated cells: N 5 4 for all groups except
SCH23390, N 5 7; and SCH23390 1 DA, N 5 5. *P , 0.05, ANOVA.
Fig. 1. Dopamine (DA) inhibits sodium/hydrogen exchanger-subtype 3
(NHE-3) activity: Dose and time dependence. NHE-3 activity was as-
sayed in opossum kidney (OK) cells by microfluorimetry as the rate
of Na1-dependent intracellular pH (pHi) recovery after acidification.
Results are expressed as the percentage of activity of control. (A) DA
was applied for 15 (j) or 30 ( ) minutes at the indicated concentrations.
Bars and error bars represent means and standard errors, respectively
(N, number of independent experiments: 1026 mol/L, N 5 4; 1025 mol/L,
N 5 6; 1024 mol/L, N 5 7; 1023 mol/L, N 5 4). Asterisks indicate
statistical significance compared with control (*P , 0.05, ANOVA).
(B) DA 1024 mol/L was applied for the indicated duration. Circles and
error bars represent means and standard errors, respectively (N, number
of independent experiments: 5 min, N 5 4; 10 min, N 5 6; 15 min, N 5
7; 30 min, N 5 4; 45 min, N 5 4; 60 min, N 5 3). Open circles represent
the readdition of fresh DA at 60 minutes, and the assay was performed
at 70 minutes (N 5 4). Asterisks indicate statistical significance com-
Fig. 3. DA receptor type 2 (DA2) pathway. Data are expressed aspared with control (*P , 0.05, ANOVA).
percentage activity of control. Bars and error bars represent means and
standard errors, respectively. Abbreviations are: Bromo, bromocryp-
tine; Quin, quinpirole; DA, dopamine. OK cells were incubated for 15
minutes with DA (1025 mol/L), the DA2 agonists bromocriptine (1026
mol/L), or quinpirole (1025 mol/L). The effect of DA was also examinedDA2 agonist potentiated the inhibition of NHE-3 activity
in the presence of the DA2 antagonist sulpiride (1026 mol/L). Numberby the DA1 agonist (DA2 1 DA1 vs. DA1 alone, P , of independent experiments (N) each consisting of a pair of control
0.05, ANOVA; Fig. 4). The additive effect can be elimi- and agonist(s)-treated cells: N 5 8 for all groups except DA, N 5 10,
and sulpiride 1 DA, N 5 12. *P , 0.05, ANOVA.nated by the addition of the DA2 antagonist sulpiride,
indicating that quipirole and bromocryptine are not sim-
ply cross-reacting with DA1 (Fig. 4). These studies sug-
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Fig. 4. Inhibition of NHE-3 by DA1 and DA2 agonists. Data are ex-
pressed as percentage activity of control (h). Bars and error bars repre-
sent means and standard errors, respectively. Abbreviations are: Fen,
fenoldopam; Bromo, bromocryptine; Quin, quinpirole. OK cells were
incubated for 15 minutes with fenoldopan alone (1024 mol/L) or in
combination with either DA2 agonists (bromocriptine, 1025 mol/L or
quinpirole 1025 mol/L) or DA2 agonists in the presence of DA2 antago-
nist (sulpiride 1025 mol/L). Number of independent experiments (N)
each consisting of a pair of control and agonist(s)-treated cells: N 5 4
for all groups except fenoldopam 1 quinpirole, N 5 6; fenoldopam 1
quinpirole 1 sulpiride, N 5 5. *P , 0.05, ANOVA.
Fig. 6. Inhibition of NHE-3 by DA: Role of the protein kinase C (PKC)
pathway. (A) Data are expressed as percentage activity of control. Bars
and error bars represent means and standard errors, respectively. OK
cells were incubated for 15 minutes with DA (1025 mol/L) or PMA
(1027 mol/L) with or without the PKC inhibitor calphostin C (1028 mol/L).
Number of independent experiments (N) each consisting of a pair of
control and agonist(s)-treated cells: N 5 4 for all groups; *P , 0.05,
ANOVA. (B) PKCa translocation assay. OK cells were incubated with
the phorbol ester PMA (1027 mol/L), DA1 agonist SKF38393 (1026 mol/L),
DA2 agonist bromocriptine (1026 mol/L), or DA (1025 mol/L) for 30
minutes. After lysis, 100 mg solubilized total cellular protein was sepa-
rated into membrane (M) and cytosolic (C) fractions, fractionated by
SDS-PAGE, and probed with anti-PKCa. Homogenized rat cortex
served as a positive control. Two independent experiments showedFig. 5. Inhibition of NHE-3 by DA: Role of the protein kinase A
similar results.(PKA) pathway. Data are expressed as percentage activity of control
(h). Bars and error bars represent means and standard errors, respec-
tively. OK cells were incubated for 15 minutes with DA1 agonist
SKF38393 (1026 mol/L) or DA (1025 mol/L) with or without the PKA
inhibitor H89 (1026 mol/L). Number of independent experiments (N)
each consisting of a pair of control and agonist(s)-treated cells: N 5 4
for all groups. *P , 0.05, ANOVA.
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gest that DA1 and DA2 receptors act synergistically to
regulate NHE-3 activity.
Acute inhibition of NHE-3 activity by DA: PKA and
PKC pathways
H89 at a concentration of 1026 mol/L is a potent inhibi-
tor of PKA (Ki 5 0.05 mmol/L) [61]. The inhibitory effect
of 1024 mol/L 8Br-cAMP on NHE-3 activity was reduced
from 36 to 7% in the presence of 1026 mol/L H89. H89
alone had no significant effect on NHE-3 activity (2%
inhibition, P 5 0.57, ANOVA; Fig. 5). The inhibition of
NHE-3 activity by the DA1 agonist SKF38393 (1026 mol/L)
was reduced from 20 to 5% in the presence of H89
(SKF38393 1 H89 vs. control, P 5 0.52, ANOVA). On
the other hand, DA (1025 mol/L 3 5 min) still had a
significant effect on NHE-3 activity in the presence of
H89, although the inhibition was reduced from 34 to
17% (DA 1 H89 vs. control, P , 0.05; DA 1 H89 vs.
DA, P , 0.001, ANOVA). Pretreatment of cells with
H89 for four hours prior to DA addition showed similar
results (data not shown). These results suggest that the
inhibition of NHE-3 by DA1 agonist is mediated entirely
by PKA, whereas the DA-induced inhibition is only par-
tially dependent on PKA.
Since DA1 agonists have been shown to activate phos-
pholipase C in renal cortical membranes [46, 47] and
PKC activation inhibits apical membrane NHE activity
in OK cells [54], we examined whether PKC mediates
part of the DA-induced inhibition of NHE-3. The PKC
inhibitor calphostin C (1028 mol/L) had no effect on the
DA (1025 mol/L)-induced inhibition of NHE-3, while
the effect of PMA was completely blocked by calphostin
C (Fig. 6A). We further tested whether DA (1024 mol/L),
SKF38393 (1026 mol/L), or bromocriptine (1026 mol/L)
induced activation of PKC. We screened for reactivity
of OK cell PKC isoforms a, b, g, d, and e using rat-specific
antiserum and found labeling predominantly with anti-
PKCa and PKCb2 (data not shown). Using the transloca-
tion assay, we found that neither DA, DA1, nor DA2
specific agonists induced translocation of PKCa (Fig. 6B).
The phorbol ester PMA (1027 mol/L), a known potent
activator of PKC, served as positive control. Similar find-
ings were obtained with PKCb2 (data not shown). These
results are in agreement with the functional studies (Fig.Fig. 7. NHE-3 protein phosphorylation. (A) NHE-3 was phosphory-
lated in vivo (DA 1025 mol/L for 30 min) in OK cells, immunoprecipi- 6A) that PKC is not involved in DA’s regulation of
tated, and resolved by SDS-PAGE. 32P-NHE-3 and NHE-3 antigen (Ag) NHE-3 in OK cells.
were determined by autoradiography and immunoblot sequentially on
the same nitrocellulose filters. Both signals were quantitated by densi-
Phosphorylation of NHE-3: Whole proteintometry. One experiment is shown in the top panel. Bar graph summa-
rizes 20 independent experiments, each consisting of a pair of control We examined phosphorylation of NHE-3 with two ap-
and DA-treated cells. The y axis represents NHE-3 phosphorylation
proaches: 32P incorporation and mobility shift. Figure 7Anormalized to antigen. The bars and error bars represent means and
standard errors, respectively (*P , 0.02, t test). (B) NHE-3, 32P-labeled inset shows a 32P labeling experiment. There is variability
in vivo from OK cells treated with agonist, was immunoprecipitated, in changes in NHE-3 whole protein phosphorylation in
gel purified, and hydrolyzed to single amino acids. (C) Equal cpms were
response to DA due to variations in the baseline phos-resolved by two-dimensional electrophoresis along with cold phosphoa-
mino acid standard (PS, phosphoserine; PT, phosphothreonine; PY, phorylation of constitutive sites on NHE-3 (phosphopep-
phosphotyrosine). Three experiments showed similar results. tide maps; discussed later in this article). When phosphor-
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Fig. 8. NHE-3 mobility shift assay and in vitro alkaline phosphatase
treatment. (A) AP-1 fibroblasts expressing rat NHE-3 was labeled with
32P in vivo and activated by the phorbol ester PMA, and NHE-3 was
immunoprecipitated and resolved on SDS-PAGE for autoradiography
and immunoblot. Two lanes on the right represent the same samples
treated with alkaline phosphatase in vitro. The arrows mark the mobility
of dephosphorylated NHE-3. (B) Time and dose response of DA-
induced NHE-3 phosphorylation using the mobility shift assay. One
representative experiment showing immunoprecipitated NHE-3 from
OK cells incubated with DA at the specified concentrations and dura-
tions. The panel at the far right shows mobility after in vitro alkaline
phosphatase treatment of immunoprecipitated NHE-3. (C) Time and
dose response of DA-induced NHE-3 phosphorylation using the mobil-
ity shift assay. Quantitated size shifts data (h; right y axis) are superim-
posed on the NHE-3 activity data (d; left y axis) summarized from
Figure 1 A and B. (Top panel, time dependence; bottom panel, dose
dependence). Total number of size shift experiments performed 5 N:
dose–response, 1026, N 5 3; 1025, N 5 5; 1024, N 5 5; 1023, N 5 5;
time course, 10 min, N 5 3; 30 min, N 5 3; 60 min, N 5 3.
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Fig. 9. Tryptic phosphopeptide maps. OK cells were 32P labeled and treated for 30 minutes with the indicated agonists: (A) Control, (B) cAMP
1024 mol/L, (C) SKF38393 1026 mol/L, (D) bromocriptine 1026 mol/L, or (E) DA 1024 mol/L. NHE-3 was immunoprecipitated, gel purified, trypsin
digested, resolved by electrophoresis and chromatography, and visualized by autoradiography. Shown are representative phosphopeptide maps for
each experimental condition (total number of maps for control, N 5 12; DA, N 5 12; cAMP, N 5 6; SKF38393, N 5 6; bromocriptine, N 5 6).
Phosphopeptides are arbitrarily labeled A–K.
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phosphorylation in response to DA are presented in
Figure 8C, where the summarized size shift data are
superimposed on NHE-3 activity data reproduced from
Figure 1 A and B. The DA-induced size shift approxi-
mately parallels the DA-induced inhibition of NHE-3
activity. These findings are congruent with the notion
that NHE-3 phosphorylation is functionally important
in the regulation of its activity.
NHE-3 phosphorylation pattern with cAMP, DA,
DA1, and DA2 agonist
Tryptic digests of NHE-3 phosphorylated in vivo in
OK cells treated with cAMP (1024 mol/L), SKF38393
(1026 mol/L), bromocriptine (1026 mol/L), DA (1024
mol/L), or control were examined. A maximum of about
14 phosphopeptides were seen in all the maps, and the
most consistently observed 12 phosphopeptides were ar-
bitrarily labeled A to L (Fig. 9). Compared with control,
phosphopeptides A, F, and J were consistently increased
in all four groups. The phosphorylation pattern of cAMP
and the DA1 agonist SKF38393 was nearly identical with
a consistent increase in phosphopeptides B, I, H, and K.
A comparison of maps from DA and DA2 agonist re-
vealed a strong resemblance, in particular, the complete
Fig. 9. Continued. de-phosphorylation of B compared with control, the lack
of phosphorylation of either I or H, and the reduced
phosphorylation of E compared with DA1. This pattern
of phosphorylation was surprising in light of the lack ofylation was normalized to antigen and analyzed in a paired
effect of DA2 alone on NHE-3 function.fashion, a significant increase of whole NHE-3 phosphory-
lation of 55 6 35% could be detected (1024 mol/L, 30 min,
N 5 20 pairs, P , 0.02). Phosphoamino analysis revealed DISCUSSION
mainly phosphoserines and only minimal phosphothreo- The proximal tubule autocrine/paracrine DA system
nine (1%) and phosphotyrosine (1%) (Fig. 7B). We also plays a critical role in NaCl homeostasis under physio-
found no labeling of NHE-3 by a monoclonal antiphos- logic conditions [1–8]. In addition, abnormalities in de-
photyrosine antibody in control, SKF38393 (1026 mol/L), fective proximal tubule DA synthesis or DA receptor
bromocriptine (1026 mol/L), or DA (1024 mol/L)-treated coupling have been implicated to play a pathogenic role
cells (data not shown). The basis of the mobility assay in two rodent models, the Dahl salt sensitive and the
of NHE-3 phosphorylation rests on the fact that phos- spontaneously hypertensive rat [62–71], as well as human
phorylated NHE-3 exhibits slower electrophoretic mi- [72–76] polygenic hypertension. Despite significant ad-
gration on polyacrylamide gels. Figure 8A shows a con- vances made in recent years, understanding of the proxi-
trol experiment validating the mobility shift assay done mal tubule autocrine/paracrine DA system is still rather
with rat NHE-3 transfected into AP-1 fibroblasts. NHE-3 fragmented. The present study focuses on one aspect
phosphorylation was increased by the phorbol ester of this autocrine/paracrine system: the proximal tubule
PMA, resulting in a slowing of mobility. Treatment of apical membrane Na/H exchanger, which is a major ef-
cell membranes with alkaline phosphatase completely fector of DA action.
eliminated the 32P on NHE-3, increased NHE-3 mobility, The proximal tubule reabsorbs over 50% of glomerular
and abrogated the PMA-induced size shift. We used filtrate [77] and contributes significantly to DA-induced
the mobility shift assay to examine the effect of DA at natriuresis. All of the transcellular NaCl absorption in
concentrations 1026 to 1023 mol/L, and at 10, 30, and 60 the proximal tubule is mediated by the apical membrane
minutes of incubation. A representative blot is shown Na/H exchanger [78], which is the NHE-3 isoform based
in Figure 8B. Similar to the fibroblast data, alkaline phos- on pharmacokinetic [79], immunohistochemical [49–51],
phatase treatment increased NHE-3 mobility at baseline and genetic evidence [80]. Previous studies using renal
and completely eliminated the mobility shift induced by cortical slices, suspended tubules, and apical membrane
vesicles have shown acute inhibition of apical Na/H ex-DA. The commensurate changes in NHE-3 function and
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change activity by DA [22–27]. In OK cells in which was a less potent inhibitor of NHE-3 activity in the pres-
ence of DA2 antagonists. Second, when DA1 and DA2NHE-3 is expressed on the apical surface, DA acutely
and reversibly inhibited NHE-3 activity in a dose- and agonists were administered together, the inhibition was
greater than that of DA1 alone. Third, although DA2time-dependent fashion from either the apical or basolat-
eral side. This is consistent with the acute natriuresis agonist did not modify NHE-3 activity in OK cells, it
induced a pattern of phosphorylation of NHE-3 that isinduced by DA [17, 18, 21] and the presence of both
apical and basolateral DA receptors in the proximal tu- very similar to that of DA. In fact, a comparison of
phosphopeptide maps revealed that the DA map resem-bule [35, 36], although basolateral DA application to
intact tubules has been inconsistent on volume absorp- bles the DA2 more than the DA1 map. It is conceivable
that although DA2 activation is insufficient to modifytion [18, 21].
Dopamine receptor subtype-1 receptors play a major NHE-3 activity, it may alter NHE-3 phosphorylation in
such a way that it optimizes the DA effect.role in mediating the DA-induced inhibition of NHE-3
in OK cells, based on the fact that DA1 blockade abro- The inhibition of NHE-3 activity in response to DA
is associated with an increase in NHE-3 phosphorylationgated the effect of DA on NHE-3 activity and that only
DA1 but not DA2 agonists when given alone, inhibited as measured by 32P incorporation, phosphopeptide map-
ping, and mobility shift. Phosphopeptide maps revealedNHE-3 activity. This is in agreement with studies in
which DA1 and DA2 agonists were added to either corti- multiple sites of phosphorylation on NHE-3, all of which
appeared to be on serine residues. This is consistentcal slices [22, 26], vesicles [25, 27], or the perfused tubule
[21]. DA1 agonists likely inhibit NHE-3 via PKA-medi- with the presence of multiple serines on the cytoplasmic
domain of opossum NHE-3 with neighboring peptideated pathways in OK cells, as the DA1 effect is blocked
by PKA inhibition similar to previous studies in cortical sequences conforming to consensus kinase substrate sites
[52]. Parallel changes in NHE-3 activity and phosphory-slices [22]. In addition, the pattern of NHE-3 phosphory-
lation by DA1 agonist is identical to 8Br-cAMP. How- lation have been described in transfected fibroblasts [55,
58, 86, 87], cultured epithelial cells [88, 89], and the intactever, our current data do not rule out the existence of
non–PKA-mediated pathways as suggested by Felder et rat kidney [90]. Activation of NHE-3 by endothelin B
receptor was also accompanied by changes in multipleal [26]. Albrecht and coworkers proposed that Gas and
bg heterodimers mediate the non–PKA-dependent DA1 phosphoamino acids on NHE-3 [88]. The permissive role
of phosphorylation of specific serine residues of rateffect [81]. The effect of DA on Na-phosphate cotrans-
port in OK cells also suggests the possible involvement NHE-3 for regulation of activity has been described in
transfected fibroblasts [58, 86]. The comparable time andof pathways other than PKA or PKC [82]. Although
DA1 receptor has been shown to be coupled to the phos- dose response between NHE-3 phosphorylation and ac-
tivity in response to DA is supportive, but certainly notpholipase C/PKC pathway in renal cortex [46, 47], inhibi-
tion of phospholipase C did not block the effect of fenol- proof of a causal relationship between NHE-3 activity
and phosphorylation. However, the fact that DR2 agonistdopam on Na/H exchange activity in apical membrane
vesicles [83]. PKC does not play a role in the inhibition induced changes in NHE-3 phosphorylation but not ac-
tivity indicates that phosphorylation alone is insufficientof NHE-3 by DA in OK cells.
While the importance of DA1 receptor is evident, the to regulate NHE-3 activity, and other regulatory factors
are likely required. Similar findings have been describedrole of DA2 receptor is less clear. The fact that DA2
agonist per se does not affect NHE-3 activity is against in the acute regulation by NHE-3 by PKC where phos-
phorylation per se is insufficient for regulating NHE-3a significant role of the DA2 receptor in regulating
NHE-3 in OK cells. The question still remains as to activity [87, 91]. One plausible model is that although
DA2 agonists induce the appropriate phosphorylationwhether DA2 has any role in modulating the DA effect
on NHE-3. Both DA1 and DA2 pathways appear to be changes in NHE3, it lacks the activation of the other yet
unknown necessary cofactors to regulate NHE3 activity.involved in the DA-induced inhibition of Na,K-ATPase
[30, 31]. For Na-dependent phosphate transport, DA1 The dephosphorylation of phosphopeptides B, I, E,
and H by DA and DA2 agonist is particularly interesting.and DA2 have been postulated by some investigators to
exert opposing effects [84], but the role of DA2 was The execution of the DA1-activated A kinase activity
has been shown to be dependent or at least enhanced bydisputed by others [82, 85]. In apical membrane vesicles,
although DA2 agonists per se has no effect on NHE-3 phosphorylation of threonine 34 on DARPP-32, which
assumes potent antiprotein phosphatase-1 activity [92, 93].activity, both DA1 and DA2 agonists inhibits the stimula-
tion of NHE-3 activity by angiotensin II [27]. In the In the central nervous system, DA2 agonists can eliminate
a major inhibitor of protein phosphatase by dephosphor-perfused tubule, epinephrine-stimulated volume flux was
inhibited 22% by DA but only 17% by DA1 agonist [21]. ylating and inactivating DARPP-32 possibly through a
calcineurin-dependent pathway [93, 94]. In addition toThree observations from this study further add to the
model that DA2 receptors may play a role. First, DA deactivation of a phosphatase inhibitor, the cytoplasmic
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on dopamine production in rat kidney. Am J Physiol 260:E675–loop of the DA2 receptor couples directly to spinophilin E679, 1991
[95, 96]. Spinophilin can simultaneously bind to DA2 9. Baines AD, Chan W: Production of urine free dopamine from
L-DOPA. Life Sci 26:253–259, 1980receptor, F-actin, and protein phosphatase-1 potentially
10. Chan YL: Cellular mechanisms of renal tubular transport ofconstituting a signaling complex connecting DA2 recep- L-DOPA and its derivatives in the rat: Microperfusion studies.
tor activation to a substrate of phosphatase [95, 96]. The J Pharmacol Exp Ther 199:17–24, 1976
11. Hayashi M, Yamaji Y, Kitajima W, et al: Aromatic amino acidmechanism of direct activation of protein phosphatase
decarboxylase activity along the at nephron. Am J Physiol 258:F28–by DA2 has not been established. It is conceivable that F33, 1990
DA dephosphorylates NHE-3 in the proximal tubule via 12. Hagege J, Richet G: Proximal tubule dopamine histofluorescence
in renal slices incubated with L-DOPA. Kidney Int 27:3–8, 1985a DA2-coupled phosphatase.
13. Goldstein DS, Stull R, Eisenhofer G, et al: Urinary excretionIn summary, we propose the following model: Activa-
of dihydroxylphenylalanine and dopamine during alteration of di-
tion of the DA1 receptor alone is necessary and sufficient etary salt intake in man. Clin Sci 76:517–522, 1989
14. McDonald RH, Goldberg LI, McNay JL, et al: Effect of dopa-to inhibit NHE-3 activity. The DA1 receptor acts by stimu-
mine in man, augmentation of sodium excretion, glomerular filtra-lating PKA, which then phosphorylates NHE-3. Although
tion rate and renal blood flow. J Clin Invest 43:1116–1124, 1964
DA2 stimulation is neither necessary nor sufficient to 15. Chapman BJ, Horn NM, Munday KA, et al: The actions of dopa-
mine and of sulpiride on regional blood flows in the rat kidney.inhibit NHE-3, DA2 activation may have a synergistic
J Physiol 298:437–452, 1980role with DA1 activation in regulation of NHE-3 by mod- 16. Hollenberg NK, Adams DF, Mendell P, et al: Renal vascular
ifying NHE-3 phosphorylation. One possible mechanism responses to dopamine: Hemodynamic and angiographic observa-
tions in normal man. Clin Sci Mol Med 45:733–742, 1973is the involvement of a DA2-activated phosphatase. Path-
17. Davis BB, Walter MJ, Murdaugh HV: The mechanism of theways other than PKA mediating the inhibition of NHE-3 increase in sodium excretion following dopamine infusion. Proc
likely exist and are not ruled out in our study. Soc Exp Biol Med 129:210–213, 1968
18. Bello-Reuss E, Pastoraiza-Munoz E, Colindres RE: Dopamine
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